At Avigen, we are developing a proprietary microfluidic platform for the next generation of preclinical immunotherapy research and development. By assessing cellular avidity at high-throughput, we rapidly identify, sort, and isolate the most therapeutically valuable, target-specific cells from a broad pool of drug candidates.